Share this Post!

In compliance with Republic Act No. 11032 otherwise known as the Ease of Doing Business (EODB) and Efficient Government Delivery Act of 2018 and Citizen’s Charter 2021, FDA modified the Electronic Portal (E-portal) for registration of raw materials and prepackaged processed food products. The features of the modified E-portal version .2 includes pre-assessment step wherein application are pre-assessed based on completeness of documentary requirements prior to payment and printing of Certificate of Product Registration (CPR) by the client. Applications filed in modified E-portal v.2 shall be processed within 20 working days from the date of posting of payment.

The FDA would like to harness support from the food industry in the implementation of EODB by postponing their filing of applications during the transition period from 01-07 March 2021. These seven (7) days applications holiday will enable the Center for Food Regulation and Research (CFRR) to finish processing all pending food registration applications filed in the old E-portal before the full implementation of E-portal v.2 on 08 March 2021 and ensure smooth implementation of the new processing time of 20 working days as prescribed by EODB. During this transition period, the current E-portal system will be closed. No food registration application (initial/amendment/renewal/reapplication/amendment data capture/ renewal data capture/ reapplication data capture) may be filed or created in the old E-registration portal.

Any food registration application shall be filed in the E-portal v. 2 effective 08 March 2021. Applications filed using E-portal v.2 shall be processed at once following the procedures in FDA Circular 2020-033. This Advisory is issued to give all concerned food business operators sufficient time to prepare prior to the imposition of registration applications holidays. FDA reiterates its commitment to process food registration applications within the prescribed timeline in the new Citizen’s Charter based on EODB.

Attachment:-> FDA Advisory No.2021-0283